Categories: BUSINESS

US tariff heat: Fitch says Indian firms face limited direct hit; pharma sector seen at risk if duties widen

Fitch Ratings cautions that while Indian corporates have limited direct exposure to current US tariffs, sectors like pharmaceuticals could face risks if further measures are imposed. The US has levied a 25% tariff on Indian goods since August 7, 2025, with another 25% due on August 27, due to India’s Russian oil imports. US tariff
Sumitra

Share
Published by
Sumitra
Tags: #pharma sector#US tariff
1 year ago

Recent Posts

West Asia crisis: Government ready with energy, fertiliser stocks

4 hours ago

Keeping all data centres sovereign, says RBI governor

4 hours ago

IDFC First Bank Q2 profit nearly triples to Rs 1,045 crore; loan assets rise 30%

In Q2 FY27, IDFC First Bank showcased an impressive profit surge of 196.5 percent year-on-year,…

1 day ago

Kotak Mahindra Bank Q2 results: Consolidated net profit jumps 26% to Rs 5,645 crore

Kotak Mahindra Bank reported an impressive 26% growth in its consolidated net profit for the…

1 day ago

Upper layer NBFCs have to list: RBI guv on Tatas; dispels doubts on Sept order

RBI governor Sanjay Malhotra’s comments also suggest Tata Sons is in breach of RBI rules.…

2 days ago

Record haul: Jio IPO collects Rs 7.5 lakh crore; nearly 1.3 crore investors make bids

In the unofficial market, speculators are betting that the company will be listing at about…

2 days ago